Pharma News

AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has approved DATROWAY (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval makes DATROWAY the first TROP2-directed antibody-drug conjugate (ADC) approved in the United States for first-line treatment in this patient population.

Scientists at Nanyang Technological University, Singapore have developed an ultra-small surgical robot capable of performing five different medical functions wirelessly inside the body, marking a major step toward more precise and minimally invasive treatments.

India’s largest pharmaceutical company, Sun Pharmaceutical Industries has reported robust financial results for the financial year ended March 31, 2026, while also announcing a final dividend of ₹5 per equity share for shareholders.

Glenmark Pharmaceuticals announced that its US-based subsidiary, Glenmark Pharmaceuticals Inc., USA, has agreed to settle long-running antitrust litigation in the United States related to alleged price-fixing and anti-competitive practices in the generic drug market.

According to the company’s regulatory filing submitted to the stock exchanges, Glenmark USA will pay a total settlement amount of 29.628 million USD in annual instalments over five years. The settlement is still subject to approval by the court overseeing the litigation.

In a major breakthrough for liver disease treatment, Gilead Sciences has received accelerated approval from the U.S. FDA for Hepcludex (bulevirtide-gmod), making it the first and only approved therapy for chronic Hepatitis Delta Virus (HDV) infection in the United States.

The U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis (advanced liver scarring) or with compensated cirrhosis. Bulevirtide is the first FDA-approved treatment for chronic HDV infection, a serious and life-threatening condition that can cause rapid development of liver fibrosis (scarring), liver cancer, liver failure, and even death.

Gilead Sciences and the World Health Organization have expanded their long-standing partnership to accelerate the elimination of visceral leishmaniasis (VL), also known as kala-azar, one of the world’s deadliest parasitic diseases.